The Veeda Newsletter


India: USFDA Records Highest Number Of Novel Drug Approvals In 2018

The approval and launch of new medicines/biological products for marketing often means the availability of new treatment for patients and advancement in health care.
Read more at:

Compulsory Licensing of Pharmaceutical Patents in India

The trend of continued rejection of compulsory license applications in India goes against the local generic drug manufacturers and public health safeguards incorporated in the Indian patent law.
Read more : :

Indian drugmakers urged to tap cancer market and innovation

Shifting focus from generic drugs to specialty drugs amidst continued price erosion in the USA, Indian.
Read more :

Indian pharma players need to explore new regions for exports

Indian pharma industry, worth $34 billion in 2018, has exhibited huge potential and is expected to grow at a compound annual growth rate (CAGR) of 15 per cent.
Read more :

New rules sweeten the deal for clinical trials by Indian pharma cos

The latest set of clinical trial rules, likely to be notified in March, will fast-track proposal clearances for Indian companies rather than their multinational counterparts.
Read more :
Contact Us